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Abstract
Background: Potent anthrax toxin neutralizing human monoclonal antibodies were generated from peripheral
blood lymphocytes obtained from Anthrax Vaccine Adsorbed (AVA) immune donors. The anti-anthrax toxin
human monoclonal antibodies were evaluated for neutralization of anthrax lethal toxin in vivo in the Fisher 344
rat bolus toxin challenge model.
Methods: Human peripheral blood lymphocytes from AVA immunized donors were engrafted into severe
combined immunodeficient (SCID) mice. Vaccination with anthrax protective antigen and lethal factor produced
a significant increase in antigen specific human IgG in the mouse serum. The antibody producing lymphocytes were
immortalized by hybridoma formation. The genes encoding the protective antibodies were rescued and stable cell
lines expressing full-length human immunoglobulin were established. The antibodies were characterized by; (1)
surface plasmon resonance; (2) inhibition of toxin in an in vitro mouse macrophage cell line protection assay and
(3) in vivo in a Fischer 344 bolus lethal toxin challenge model.
Results: The range of antibodies generated were diverse with evidence of extensive hyper mutation, and all were
of very high affinity for PA83~1 × 10-10-11M. Moreover all the antibodies were potent inhibitors of anthrax lethal
toxin in vitro. A single IV dose of AVP-21D9 or AVP-22G12 was found to confer full protection with as little as
0.5× (AVP-21D9) and 1× (AVP-22G12) molar equivalence relative to the anthrax toxin in the rat challenge
prophylaxis model.
Conclusion:  Here we describe a powerful technology to capture the recall antibody response to AVA
vaccination and provide detailed molecular characterization of the protective human monoclonal antibodies. AVP-
21D9, AVP-22G12 and AVP-1C6 protect rats from anthrax lethal toxin at low dose. Aglycosylated versions of
the most potent antibodies are also protective in vivo, suggesting that lethal toxin neutralization is not Fc effector
mediated. The protective effect of AVP-21D9 persists for at least one week in rats. These potent fully human anti-
PA toxin-neutralizing antibodies are attractive candidates for prophylaxis and/or treatment against Anthrax Class
A bioterrorism toxins.
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Background
Unlike diphtheria, tetanus and botulinum, anthrax infec-
tion manifests itself due to toxin mediated immune dys-
function, which permits the anthrax bacteria to evade
immune surveillance and thus disseminate throughout
the body and reach extremely high levels. Very high levels
of toxins produced later in the infection may also facilitate
subsequent rapid onset of death due to massive organ fail-
ure. Hence inhibiting anthrax toxins early may change the
course of infection and may allow a vigorous immune
response against the bacteria and the toxins; in essence
passive immunity against the toxins may facilitate active
immunity in a natural exposure. Anthrax toxin, which
consists of three polypeptides protective antigen (PA, 83
kDa), lethal factor (LF, 90 kDa) and edema factor (EF, 89
kDa), is a major virulence factor of Bacillus anthracis. The
LF and EF components are enzymes that are carried into
the cell by PA. The combination of PA and LF forms lethal
toxin [1-3]. Anthrax toxin enters cells via a receptor-medi-
ated endocytosis [4,5]. PA binds to the receptor and is
processed (PA, 63 kDa), which forms a heptameric ring
that delivers the EF or LF to the cytosol. The path leading
from PA binding to cells via TEM-8 [5] or CMG2 [6], furin
processing, heptamer formation, LF or EF binding to hep-
tamer, or the translocation of EF/LF to the cytosol pro-
vides multiple sites for molecular intervention.
The PA plays an elaborate yet critical role in virulence and
has been the main target for immune disruption of the
anthrax toxins. The role of the PA component in the vac-
cine was established soon after the discovery of the toxin
[7]. In the 1880's it had been demonstrated that inocula-
tion of animals with attenuated strains of B. anthracis led
to protection [8]. An improved unencapsulated avirulent
variant of B. anthracis was developed in the late 1930's for
veterinary use [9,10]. The observation that exudates from
anthrax lesions could provide protection in laboratory
animals [11] led to the evaluation of filtrates of culture of
B. anthracis as vaccines [12]. The current licensed anthrax
vaccine developed more than half a century ago is based
on B. anthracis culture filtrate [13], utilizes B. anthracis
strains that produce more PA under certain growth condi-
tions [14,15]. The standard immunization schedule with
this crude PA preparation with aluminium hydroxide,
involves 3 subcutaneous injections at 0, 2 and 4 weeks,
and 3 booster at 6, 12 and 18 months, and it is suggested
that an annual booster is required to maintain immunity.
In the event of an intentional or inadvertent exposure to
B. anthracis aerosolized spore [16], immediate immunity
is required. This may be attained by passive immuniza-
tion. Passive immunity against B. anthracis has been dem-
onstrated with polyclonal antibodies in laboratory
animals [17,18]. More recently several groups have dem-
onstrated passive efficacy of recombinant antibody frag-
ments derived and optimized by phage display directed
against PA in Fisher 344 rats challenged with lethal toxin
[19,20]. Neutralizing anthrax toxins immediately may
allow the immune system to recognizes components of
the  B. anthracis bacteria and mount an appropriate
response and significantly alter the course of infection.
Secondly, toxin neutralization may also prevent death.
A passive immunization approach would provide imme-
diate immunity, which would complement antibiotic
therapy.
Here we describe the generation of a panel of potent
human monoclonal antibodies derived from anthrax vac-
cine adsorbed immune donors. Protection against anthrax
toxin challenge in an in vitro cell culture assay correlates
well with affinity, with the highest affinity antibody AVP-
21D9 (Kd = 82 pM) exhibiting the most potent toxin inhi-
bition. Moreover, we report a panel of fully human anti-
bodies generated from AVA vaccinated donors using
Xenerex™ technology protect Fisher 344 rats from anthrax
intoxication in vivo.
Methods
Selection of donors
We have an Institutional Review Board (IRB) approved
protocol to obtain units of blood from donors at Avanir
Pharmaceuticals. Volunteer donors informed consent
were obtained. Volunteers serum obtained at the time of
blood collection by venipuncture from anthrax-vacci-
nated donors were pre-screened against a panel of anti-
gens (including components of the anthrax exotoxin PA
and LF) in an ELISA for both IgG and IgM. An internal cal-
ibrator was incorporated into each assay consisting of a
control antiserum containing both IgG and IgM anti-teta-
nus toxoid. The IgG and IgM titres were compared across
assays performed on different days, thereby permitting
more robust comparisons of the entire donor panel.
Engraftment of SCID mice with human PBMC from pre-
selected AVA immune donors
Peripheral blood mononuclear cells were separated from
whole blood of AVA immune donors by density gradient
using Histopaque (Sigma, St Louis, MO). Twelve-week-
old SCID/bg mice were each engrafted (via intra
peritoneal ip injection) with 2.5 × 107 human PBMC.
They were treated with 0.5 ml of conditioned media,
which contains 0.2 mg of the anti-CD8 monoclonal anti-
body. After 2 hours, the mice were immunized (ip) with
the recombinant PA and LF (List Laboratories Inc, Camp-
bell, CA) 2 µg each adsorbed to Alum (Imject®, Pierce,
Rockford, IL) and subsequently boosted (ip) 8 and 28
d a y s  l a t e r .  M i c e  w e r e  i n o c u l a t e d  w i t h  0 . 5  m l  o f  E B V
obtained from B95-8 cells spent conditioned culture
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were obtained from the orbital sinus, on days 15 and 30.
Two consecutive iv and ip boosts with the appropriate tox-
ins were administered (typically, 5 µg each on day 35 and
day 36; both in saline) prior to harvesting cells for fusion
on day 37. The total IgG and specific anti-PA IgG assays
combined with potency in the RAW 264.7 cell bioassay
(as described below) were determined.
Generation of human hybridomas
Splenocytes, peritoneal washes, as well as lymphoblastoid
cell line (LCL) tumors transformed by EBV, were har-
vested on day 37 from those mice showing positive test
bleeds in PA specific ELISA and the appropriate bioassay.
Human hybridomas were generated from these in sepa-
rate fusions using a mouse myeloma cell line P3X/
63Ag8.653 [21] with PEG-1500 (Sigma, St Louis, MO).
Double selection against the EBV transformed LCL and
the un-fused fusion partner was carried out using a com-
bination of HAT and Ouabain.
Variable region IgH and IgL cDNA cloning and expression
Total RNA was prepared from hybridoma cells using RNe-
asy Mini Kit (Qiagen, Valencia, CA). Mixture of VH and VL
cDNAs were synthesized and amplified in a same tube
using One-Step RT-PCR Kit (Qiagen, Valencia, CA).
Cycling parameters were 50°C for 35 min, 95°C for 15
min, 35 cycles of 94°C for 30 sec, 52°C for 20 sec and
72°C for 1 min 15 sec, and 72°C for 5 min.
Primers used for RT-PCR were:
For VHγ
Forward
a. CVH2 TGCCAGRTCACCTTGARGGAG
b. CVH3 TGCSARGTGCAGCTGKTGGAG
c. CVH4 TGCCAGSTGCAGCTRCAGSAG
d. CVH6 TGCCAGGTACAGCTGCAGCAG
e. CVH1257 TGCCAGGTGCAGCTGGTGSARTC
Reverse (located at 5' of CH1 region)
a. CγII GCCAGGGGGAAGACSGATG
For VLκ
Forward
a. VK1F GACATCCRGDTGACCCAGTCTCC
b. VK36F GAAATTGTRWTGACRCAGTCTCC
c. VK2346F GATRTTGTGMTGACBCAGWCTCC
d. VK5F GAAACGACACTCACGCAGTCTC
Reverse (located in constant region)
a. Ck543 GTTTCTCGTAGTCTGCTTTGCTCA
For VLλ
Forward
a. VL1 CAGTCTGTGYTGACGCAGCCGCC
b. VL2 CAGTCTGYYCTGAYTCAGCCT
c. VL3 TCCTATGAGCTGAYRCAGCYACC
d. VL1459 CAGCCTGTGCTGACTCARYC
e. VL78 CAGDCTGTGGTGACYCAGGAGCC
f. VL6 AATTTTATGCTGACTCAGCCCC
Reverse (located in constant region)
a. CL2 AGCTCCTCAGAGGAGGGYGG
The RT-PCR was followed by nested PCR with High Fidel-
ity Platinum PCR Mix (Invitrogen, Carlsbad, CA). An aliq-
uot (1 µl)of RT-PCR products were used for VHγ, VLκ or
VLλ specific cDNA amplification in a separate tube. At the
same time restriction enzyme sites were introduced at
both ends. Cycling parameters were 1 cycle of 94°C for 2
min, 60°C for 30 sec and 68°C for 45 sec, 35 cycles of
94°C for 40 sec, 54°C for 25 sec and 68°C for 45 sec, and
68°C for 5 min.
Each specific PCR product was separately purified,
digested with restriction enzymes, and subcloned into
appropriate mammalian full-length Ig expression vectors
as described below.
Primers for nested PCR were:
For VH γ
Forward (adding BsrGI site at 5' end)
a. BsrGIVHF2 AAAATGTACAGTGCCAGRTCACCTT-
GARGGAG
b. BsrGIVHF3 AAAATGTACAGTGCSARGTGCAGCTGKT-
GGAG
c. BsrGIVHF4 AAAATGTACAGTGCCAGST-
GCAGCTRCAGSAGJournal of Immune Based Therapies and Vaccines 2004, 2 http://www.jibtherapies.com/content/2/1/5
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d. BsrGIVHF6 AAAATGTACAGTGCCAGGTACAGCT-
GCAGCAG
e. BsrGIVHF1257 AAAATGTACAGTGCCAGGTGCAGCT-
GGTGSARTC
Reverse (including native ApaI site)
a. CγER GACSGATGGGCCCTTGGTGGA
VHγPCR products were digested with BsrG I and Apa I and
ligated into pEEG1.1 vector that is linearlized by Spl I and
Apa, I double digestion.
For VLκ
Forward (adding AgeI site, Cys and Asp at 5'end)
a. AgeIVK1F TTTTACCGGTGTGACATCCRGDTGAC-
CCAGTCTCC
b. AgeIVK36F TTTTACCGGTGTGAAATTGTRWT-
GACRCAGTCTCC
c. AgeIVK2346F TTTTACCGGTGTGATRTTGTGMTGACB-
CAGWCTCC
d. AgeIVK5F TTTTACCGGTGTGAAACGACACTCACG-
CAGTCTC
Reverse (adding SplI site, located between FR4 and 5' of
constsnt region)
a. SplKFR4R12 TTTCGTACGTTTGAYYTCCASCTTGGTC-
CCYTG
b. SplKFR4R3 TTTCGTACGTTTSAKATCCACTTTGGTC-
CCAGG
c. SplKFR4R4 TTTCGTACGTTTGATCTCCACCTTGGTC-
CCTCC
d. SplKFR4R5 TTTCGTACGTTTAATCTCCAGTCGTGTC-
CCTTG
VLκPCR products were digested with Age I and Spl I and
ligated into pEEK1.1 vector linearized by Xma I and Spl I
double digestion.
For VLλ
Forward (adding ApaI site at 5' end)
a. ApaIVL1 ATATGGGCCCAGTCTGTGYTGACG-
CAGCCGCC
b. ApaIVL2 ATATGGGCCCAGTCTGYYCTGAYTCAGCCT
c. ApaIVL3 ATATGGGCCCAGTATGAGCTGAYRCAGCY-
ACC
d. ApaIVL1459 ATATGGGCCCAGCCTGTGCTGACT-
CARYC
e. ApaIVL78 ATATGGGCCCAGDCTGTGGTGACYCAG-
GAGCC
f. ApaIVL6 ATATGGGCCCAGTTTTATGCTGACT-
CAGCCCC
Reverse (adding Avr II site, located between FR4 and 5' of
constant region)
a. AvrIIVL1IR TTTCCTAGGACGGTGACCTTGGTCCCAGT
b. AvrIIVL237IR TTTCCTAGGACGGTCAGCTTGGTSC-
CTCCKCCG
c. AvrIIVL6IR TTTCCTAGGACGGTCACCTTGGTGCCACT
d. AvrIIVLmixIR TTTCCTAGGACGGTCARCTKGGTBC-
CTCC
VLλPCR products were digested with Apa I and Avr II and
ligated into pEELg vector linearized by Apa I and Avr II
double digestion.
The positive clones were identified after transient co-
transfection by determining expression in the superna-
tants by indirect ELISA on PA coated plates. CHO K1 cells
were transfected with different combinations of IgG and
IgK cDNAs using Lipofectamine-2000 (Invitrogen,
Carlsbad, CA). The supernatants were harvested 48 – 72 h
after transfection. Multiple positive clones were
sequenced with the ABI 3700 automatic sequencer
(Applied Biosystems, Foster City, CA) and analyzed with
Sequencher v4.1.4 software (GeneCodes, Ann Arbor, MI).
Stable cell line establishment
Ig heavy chain or light chain expression vector were dou-
ble digested with Not I and Sal I, and then both fragments
were ligated to form a double gene expression vector.
CHO-K1 cells in 6 well-plate were transfected with the
double gene expression vector using Lipofectamine 2000
(Invitrogen, Carlsbad, CA). After 24 hrs, transfected cells
were transferred to 10 cm dish with selection medium (D.
MEM supplemented with 10% dialyzed FBS, 50 µM L-
methionine sulphoximine (MSX), penicillin/streptomy-
cin, GS supplement). Two weeks later MSX resistant trans-
fectants were isolated and expanded. High anti-PA
antibody producing clones were selected by measuring
the antibody levels in supernatants in a PA specific ELISAJournal of Immune Based Therapies and Vaccines 2004, 2 http://www.jibtherapies.com/content/2/1/5
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assay. MSX concentration was increased from 50 to 100
µM to enhance the antibody productivity.
Antigen specific ELISA
The presence of antibody to anthrax toxin components in
human sera, engrafted SCID mouse sera, supernatants of
hybridomas or transiently transfected CHO-K1 cells were
determined by ELISA. Briefly, flat bottom microtiter plates
(Nunc F96 Maxisorp, Rochester, NY) were coated with the
appropriate component of the Bacillus anthracis tripartite
exotoxin, such as PA or LF, diluted sera was added to the
wells for one hour at room temperature. Plates were
washed and secondary antibody, goat anti-human IgG-
HRP, Fcγ specific or goat anti-human IgM-HRP, Fcµ spe-
cific antibody were added and incubated for one hour at
room temperature. After another wash step, a substrate
solution containing OPD (O-phenylenediamine dihydro-
chloride) in citrate buffer was added. After 15 minutes, 3
N HCl was added to stop the reaction and plates were read
on a microplate reader at 490 nm.
Human Ig/κ/λ quantification by ELISA
Flat bottom microtiter plates (Nunc F96 Maxisorp) were
coated overnight at 4°C with 50 µl of goat anti-human
IgG, Fcγ specific antibody, at 1 µg/ml in PBS. Plates were
washed four times with PBS-0.1% Tween 20. Meanwhile,
in a separate preparation plate, dilutions of standards (in
duplicate) and unknowns were prepared in 100 µl volume
of PBS with 1 mg/ml BSA. A purified monoclonal human
IgG1/κ or λ protein was used as the standard and a differ-
ent IgG1/κ or λ protein serves as an internal calibrator for
comparison. Diluted test samples (50 µl) were transferred
to the wells of the assay plate and incubated for one hour
at room temperature. Plates were washed as before and 50
µl of the detecting antibody, goat anti-human kappa or
lambda-HRP was added, incubated for one hour at room
temperature, and developed as described above.
RAW 264.7 cell line in vitro bioassay
The presence of neutralizing (protective) antibody to
anthrax toxin components in human sera, engrafted SCID
mouse sera, supernatants of hybridomas or transiently
transfected CHO-K1 cells were determined using an in
vitro  protection bioassay with the mouse macrophage
RAW 264.7 target cell line [22]. Briefly, recombinant PA
(100 ng/ml) and LF (50 ng/ml) were pre-incubated with a
range of dilutions of each sample for 30 minutes at 37°C
in a working volume of 100 ul of DMEM medium supple-
mented with 10% fetal calf serum. This 100 ul volume was
subsequently transferred into a 96 well flat bottom tissue
culture plate containing 1 × 104 RAW 264.7 cells/well in
100 ul of the same medium. The culture plate was incu-
bated for 3 hours at 37°C. The lysed cells were removed
by washing. The remaining cells were assayed using the
CytoTox Assay96 kit (Promega Corp., WI) following the
manufacturer protocol. Briefly, the cells are lysed, an aliq-
uot added to a substrate mix and the lactate dehydroge-
nase activity determined spectrophometrically at 490 nm.
This assay was used to approximate the IC50 of antibodies
in conferring protection against lethal toxin.
Binding affinity determinations
BiaCore: Affinity constants were determined using the
principal of surface plasmon resonance (SPR) with a
BiaCore 3000 (BiaCore Inc.). Affinity purified goat anti-
human IgG (Jackson ImmunoResearch) was conjugated
to two flow cells of the CM5 chip according to manufac-
turer's instructions. An optimal concentration of an anti-
body preparation was first introduced into one of the two
flowcells, and was captured by the anti-human IgG. Next,
a defined concentration of antigen was introduced into
both flow cells for a defined period of time, using the flow
cell without antibody as a reference signal. As antigen
bound to the captured antibody of interest, there was a
change in the SPR signal, which was proportional to the
amount of antigen bound. After a defined period of time,
antigen solution was replaced with buffer, and the disso-
ciation of the antigen from the antibody was then meas-
ured, again by the SPR signal. Curve-fitting software
provided by BiaCore generated estimates of the associa-
tion and dissociation rates from which affinities were
calculated.
Fischer rat in vivo anthrax toxin neutralization
The in vivo anthrax toxin neutralization experiments were
performed basically as described by Ivins [23]. Male
Fisher 344 rats with jugular vein catheters weighing
between 200–250 g were purchased from Charles River
Laboratories (Wilmington, MA). Human anti-anthrax PA
IgG monoclonal antibodies AVP-21D9, AVP-22G12, AVP-
1C6, AVP-21D9.1 and AVP22G12.1 were produced from
recombinant CHO cell lines adapted for growth in serum
free media. The human IgG monoclonal antibodies were
purified by affinity chromatography on HiTrap Protein A,
dialyzed against PBS pH7.4 and filter sterilized. Rats were
anaesthetized in an Isofluorane (Abbott, Il) EZ-anesthesia
chamber (Euthanex Corp, PA) following manufacturers
guidelines. The antibody was administered via the cathe-
ter in 0.2 ml PBS/0.1%BSA pH 7.4 and at 5 minutes, 17
hours or a week later lethal toxin (PA 20 µg / LF 4 µg in
0.2 ml PBS 0.1%BSA pH 7.4/ 200 g rat) was administered
via the same route. Five animals were used in each test
group and four animals in each control IgG (Sigma, St
Louis, MO). Test and control experiments were carried out
at the same time using the same batch of reconstituted PA
and LF toxins (List Laboratories). Animals were moni-
tored for discomfort and time of death versus survival, as
assessed on the basis of cessation of breathing and heart-
beat. Rats were maintained under anesthesia for 5 hr post
exposure to lethal toxin or until death to minimizeJournal of Immune Based Therapies and Vaccines 2004, 2 http://www.jibtherapies.com/content/2/1/5
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discomfort. Rats that survived were monitored for 24
hours and then euthanized by carbon dioxide asphyxia-
tion. All experimental protocols involving animals were
reviewed and approved by the Avanir Pharmaceuticals
Institutional Animal Care and Use Committee (San
Diego, CA).
Results
Donor screening
Donors sera (X064-004b and X064-019) were screened
for IgG and IgM against tetanus toxoid, PA and LF by
ELISA. Figure 1 shows that both donors had significant
IgG responses to tetanus toxoid and some albeit low levels
of specific IgG antibody against PA and LF.
Chimeric engraft screening
The PBLs from donor X064-004b and X064-019 were
engrafted into mice designated X040-042 and X040-043
respectively. After boosting, sera from engrafted mice were
screened for human IgG against PA. In figure 2A the initial
bleed after the first boost is plotted alongside the X064-
004b donor sera. One engraft had an anti-PA IgG level
that is 9 × higher than the donor sera. Moreover in figure
2B, the second bleed from the engrafted mice, a range of
8–30 fold increase in specific anti-PA IgG is observed. This
increase in specific IgG over time in the engrafted mice is
even more pronounced in the second engraft using cells
from donor X064-019 as shown in figure 3A and 3B. The
increase in specific anti-PA IgG in the second bleed is
more than 500 fold relative to specific anti-PA in the
donor sera.
Immunoglobulin sequence analysis
Following fusion, hybridoma cells producing human
anti-anthrax PA IgG were selected and the cDNA encoding
the immunoglobulin variable regions were rescued and
sequenced. The cDNA templates were used to establish
stable CHO K1 cell lines producing antibodies. Four neu-
tralizing anti-PA antibodies were discovered by this
approach. The VH families were represented by the VH3,
VH1 and VH4. Likewise VK 1 and VL 3 represented the VL
families. Both VH and VL regions contained evidence of
hyper mutation away from the germline. The Table 1 lists
the antibodies isolated by this approach and the D and J
regions are assigned where possible using DNAPLOT in
Vbase.
Kinetics of binding
The equilibrium dissociation constants (Kd) for recom-
binant form of the antibodies were determined by
BiaCore analysis. The rate constants kon and koff were eval-
uated directly from the sensogram in the BiaCore analysis
and the Kd was deduced. The results are summarized in
Table 2. One striking feature of all the protective antibod-
ies isolated by the Xenerex Technology™ is the very slow
off rate, which contribute to the very high affinities 8.21 ×
10-11M to 7.11 × 10-10M. The slow off rate may confer sig-
nificant physiological advantages for toxin neutralization
in vivo.
In vitro lethal toxin inhibition
All the antibodies were initially selected based on binding
to PA83 and secondly on inhibition of lethal toxin in a
Raw 264.7 cell based in vitro assay. Only clones exhibiting
toxin neutralization in a qualitative assay were developed
further. The Raw 264.7 cell assay was adapted to compare
the various antibodies for potency of toxin inhibition. In
figure 4 a typical antibody dose response curve is recon-
structed to provide an estimate of the IC50 for AVP-21D9,
AVP-22G12 and AVP-1C6. Again the inhibitory potency
ranking of all the selected antibodies were reflecting the
same ranking observed for the binding to PA83.
Effect of anti-anthrax PA antibodies on protection of rats 
from lethal toxin challenge
Figure 5 illustrates the protection profile of the three anti-
bodies AVP-21D9, 22G12 and 1C6 in the rat model at two
doses 0.5× and 1× molar ratios relative to toxin challenge.
AVP-21D9 protected rats at 0.5× and no deaths were
observed in the 5 hr following toxin administration, like-
wise AVP-22G12 at 1× also showed complete protection.
However with AVP22G12 at 0.5× the time to death was
prolonged to 255 min. The administrations of lethal toxin
5 min after the infusion of 0.5× or 1× control human IgG
resulted in time to death of 85–120 min. AVP-1C6 at 1×
conferred 80% protection and at 0.5× were not protective.
Effect of antibody glycosylation on anti-anthrax PA 
antibodies on protection of rats from lethal toxin 
challenge
Site directed mutagenesis (N297Q) was used to remove
the N-glycosylation site in the Fc region. These aglyco-
sylated antibodies were designated as AVP-21D9.1 and
AVP-22G12.1 and compared to the glycosylated counter-
parts in the rat toxin challenge prophylaxis model. As
described earlier, antibody was intravenously adminis-
tered 5 minutes prior to the lethal toxin (PA/LF) chal-
lenge. Both AVP-21D9 and AVP-21D9.1 fully protected
rats against anthrax toxin with 0.5× molar excess relative
to PA toxin, whilst AVP-22G12.1 was slightly less potent
than the parent molecule at 1× as shown in figure 6.
Duration of AVP-21D9 antibody mediated protection of 
rats from lethal toxin challenge
To investigate the duration of the protection afforded by a
fully human antibody in Fisher rats AVP-21D9 was intra-
venously administered 17 hours or 1 week prior to the
lethal toxin (PA/LF) challenge. A single administration of
AVP-21D9 at 1× protected 100% when challenged 17
hours later. Over the extended period of timeJournal of Immune Based Therapies and Vaccines 2004, 2 http://www.jibtherapies.com/content/2/1/5
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ELISA panels of AVA vaccinated donors Figure 1
ELISA panels of AVA vaccinated donors Plasma samples X064-004b and X064-019 obtained at the time of blood collec-
tion by venipuncture from anthrax-vaccinated donors were pre-screened against tetanus toxoid, PA 83 and LF in an ELISA for 
both IgG and IgM.
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IgG response to PA83 in donor X064-004b engraft sera Figure 2
IgG response to PA83 in donor X064-004b engraft sera The presence of IgG antibody to anthrax toxin PA83 compo-
nents in sera of engrafted SCID mice sera were determined by ELISA after the first and second boosts. The specific levels of 
IgG and donor levels are shown. The IgG response from Donor X064-004b cells engrafted into SCID mice at day 15 (A) and 
day 30 (B).
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IgG response to PA83 in donor X064-043 engraft sera Figure 3
IgG response to PA83 in donor X064-043 engraft sera The presence of IgG antibody to anthrax toxin PA83 compo-
nents in sera of engrafted SCID mice sera were determined by ELISA after the first and second boosts. The specific levels of 
IgG and donor levels are shown. The IgG response from Donor X064-043 cells engrafted into SCID mice at day 15 (A) and day 
30 (B).
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administration of AVP-21D9 at 10 × dose showed 80%
protection. Almost all the control animals died within
120 min, one outlier had delayed time of death to 230
minutes (Figure 7).
Discussion
The engraftment of human peripheral blood lymphocytes
into severe combined immunodeficient (SCID) mice in
order to reconstitute a functional human immune system
has been reported previously [24]. However the subse-
quent rescue and immortalization of specific B-cells has
had mixed results. In this study we recruited donors that
had been actively immunized with the current licensed
anthrax vaccine (AVA). Despite vaccination the serum lev-
els of anti-PA83 specific IgG and IgM were relatively low
(2–3 µg/ml) in comparison to the anti-tetanus responses
in both donors. We utilized the SCID-HuPBL platform to
demonstrate that we could selectively direct the response
by immunization of the chimeric animals. Immunization
of the chimeric mice with recombinant PA83 resulted in a
significant increase in specific IgG in some of the
engrafted mice, in one case as high as 2 mg/ml (mouse
4152 figure 3A). In comparing the 1st bleeds (figure 2A
&3A) with the 2nd bleeds (figure 2B &3B) for both sets of
chimeric mice, it is clear that a specific response was selec-
tively enhanced in the animals upon boosting with anti-
Table 1: Human anti-anthrax PA83 antibody classification. The immunoglobulin sequence derived from the cDNA encoding the variable 
regions were used to search Vbase and the VH class, VH locus, DH and JH segments were assigned for the VH regions. Likewise VL 
class, VL locus and JL segments were assigned for the VL regions. Comparing the actual sequences and closest matched V family 
members the extent of somatic hyper mutation could be ascertained.
VH V L
Designation VH Class VH Locus # Mutations from 
germline
DH(RF) JH VL Class VL Locus # Mutations from 
Germline
JL
AVP-21D9 VH3 3–43 26 6–19(1) JH4b VKI L12 14 JK1
AVP-1C6 VH3 3–73 8 6–13(1) JH3b/a VKI L18 13 JK4
AVP-4H7 VH4 4–39 29 unknown JH6b/a VL3 3h 22 JL2/JL3a
AVP-22G12 VH3 3–11 20 unknown JH5b VL3 3r 9 JL2/JL3a
Table 2: Human anti-anthrax PA antibody kinetic binding data. The equilibrium dissociation constant (Kd) for recombinant form of the 
antibodies was determined by BiaCore analyses. The rate constants kon and koff were evaluated directly from the sensogram in the 
BiaCore analysis and the Kd was deduced.
Antibody Dissociation Constant
(KD) M
Association Rate
(kon) M-1S-1
Dissociation Rate
(koff) S-1
AVP-21D9 8.21 × 10-11 1.80 × 105 1.48 × 10-5
AVP-1C6 7.11 × 10-10 1.85 × 105 1.31 × 10-4
AVP-4H7 1.41 × 10-10 1.74 × 105 2.45 × 10-5
AVP-22G12 5.12 × 10-10 1.01 × 105 5.17 × 10-5
Determination of AVP-21D9 IC50 using RAW 264.7 264.7  cell based assay Figure 4
Determination of AVP-21D9 IC50 using RAW 264.7 
264.7 cell based assay 1.2 nM PA and 0.56 nM LF in a 96 
well assay on confluent RAW 264.7 264.7 cells cause 100% 
cell lysis. The AVP-21D9 was assessed at various concentra-
tions for the ability to inhibit the lethal toxin. From the dose 
response curve an IC50 values was estimated. AVP-22G12 
and AVP-1C6 IC50 determinations were carried out likewise.
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gen (see figure 3A &3B). However not all the chimeric
mice demonstrated such a robust response, hence it is not
a stochastic process. We speculate that in mice that
responded well to antigen challenge, we have recalled the
human memory B cell response and recruited specific
human helper T-cells. The specific recall leads to prolifer-
ation of antigen specific plasma cells. The antibody pro-
ducing cells in the chimeric mice were recovered from the
spleen and peritoneal washes in sufficient numbers to per-
mit fusion with a standard mouse myeloma
P3X63Ag8.653 [21] to form hybridomas. Others [25,26]
and we have noted that the formation of mouse/human
hybridomas using a murine fusion partner with human
derived plasma cells results in unstable hybrids, usually
these are difficult to clone, expand and isolate. We circum-
navigate this problem by rescuing the transcripts encoded
by mRNA from a small cluster of cells and generating sta-
ble recombinant CHO cell lines and testing these for the
activity. Hence the fusion with P3X63Ag8.653 with the
human cells results in hybrids of antibody-producing cell,
which permits identification of positive wells for specific
IgG production and the rescue of immunoglobulin
transcripts.
No particular heavy chain family or light chains domi-
nated the human anti-PA response. In all but two cases we
could assign DH segments usage. The array of JH and JL seg-
ments observed in the panel suggest that the approach is
capturing the diversity present in the natural response to
anthrax PA via vaccination with AVA. Another striking fea-
ture of the antibodies is the exceptional high affinity for
the target antigen and the very slow off-rates. We have
seen similar high affinities and slow off rates for anti-teta-
nus toxoid antibodies derived from engrafted SCID-
HuPBL mice boosted with antigen (data not shown). This
may be a general feature of the protective anti-bacterial
toxin response in humans.
Protection of rats from a lethal toxin challenge five minutesafter administration of antibody Figure 5
Protection of rats from a lethal toxin challenge five minutesafter administration of antibody Male Fisher 344 rats 
with jugular vein catheters weighing between 200–250 g were administered human anti-anthrax PA IgG monoclonal antibodies 
AVP-21D9, AVP-22G12, AVP-1C6, or the control human IgG in 0.2 ml PBS 0.1% BSA pH 7.4, 5 minutes later lethal toxin (PA 
20 µg + LF 4 µg/200 g rat in 0.2 ml PBS 0.1% BSA pH 7.4) was administered. The dose of antibody was 0.25 and 0.12 nmols/rat 
corresponding to 1× and 0.5× molar equivalent to the lethal toxin. Five animals were used in each test group and four animals 
in each control. Test and control experiments were carried out at the same time using the same batch of reconstituted PA and 
LF toxins. Animals were monitored for discomfort and time of death, as assessed on the basis of cessation of breathing and 
heartbeat. Rats were maintained under anaesthesia for 5 hr post exposure to lethal toxin or until death to minimize 
discomfort.
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Currently in the event of an inadvertent Bacillus anthracis
spore exposure two preventative measures can be taken. If
the risk can be assessed well in advance, vaccination can
be employed. In the event of near term or immediate post
exposure antibiotic such as Cipro may be effective.
Anthrax Vaccine Adsorbed (AVA) is the only licensed
human anthrax vaccine in the United States. The vaccine
is known to contain a mixture of cell products including
PA, LF and EF, however the exact amounts are unknown
[27]. The immunization schedule consists of three subcu-
taneous injections at 0, 2 and 4 weeks and booster vacci-
nation at 6, 12 and 18 months and it is suggested that
annual boost may be required to maintain immunity.
Mass vaccination in the event of anthrax spore release is
an unlikely scenario. First, the time taken for effectiveness
of such vaccination based on AVA or various rPA mole-
cules in development may be too short, weeks as opposed
to minutes. The utilization of antibiotic can inhibit
bacterial growth and spread, and may prevent some of the
symptoms, but the administration needs to be timely and
preferably as a prophylactic, even as such, the toxins
released during the early stages of an infection may impair
the immune system to cause lasting damage. Ideally, a
combination of approaches that inhibit anthrax bacteria
and toxins is desirable.
Human antibodies are safe and well tolerated for a range
of therapeutic indications and are logical choices for an
immediate anthrax therapeutic or prophylactic in
humans. Passive protection against anthrax toxins in rats
and anthrax infection in guinea pigs has been demon-
strated for murine monoclonal antibodies [28,29] and
polyclonal antibodies [17], respectively. Recently a
human monoclonal antibody against PA has demon-
strated efficacy in protecting rats challenged with lethal
toxin [20]. The antibody was fully protective at 0.3 nmol/
250 g rat. It is expected that exceptionally high affinity
human monoclonal antibodies against the anthrax toxin
Protection of rats from a lethal toxin challenge by aglycosylated antibody Figure 6
Protection of rats from a lethal toxin challenge by aglycosylated antibody Male Fisher 344 rats with jugular vein 
catheters weighing between 200–250 g were administered human anti-anthrax PA IgG monoclonal antibodies AVP-21D9, AVP-
22G12, the aglycosylated forms AVP-21D9.1 and AVP22G12.1 or the control human IgG in 0.2 ml PBS 0.1% BSA pH 7.4, 5 
minutes later lethal toxin (PA 20 µg / LF 4 µg in 0.2 ml/200 g rat PBS 0.1% BSA pH 7.4) was administered. The dose of antibody 
was 0.25 and 0.12 nmols/rat corresponding to 1× and 0.5× molar equivalent to the lethal toxin. Five animals were used in each 
test group and four animals in each control. Test and control experiments were carried out at the same time using the same 
batch of reconstituted PA and LF toxins. Animals were monitored for discomfort and time of death, as assessed on the basis of 
cessation of breathing and heartbeat. Rats were maintained under anaesthesia for 5 hr post exposure to lethal toxin or until 
death to minimize discomfort.
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should have a therapeutic potential to treat anthrax expo-
sure in humans. In this study we compare 3 human anti-
bodies that neutralize anthrax lethal toxin in vitro and in
vivo rat toxin challenge model. The most potent inhibitor
of the anthrax toxin AVP-21D9 protected rats with as little
as 0.5× antibody to toxin in vivo, this corresponds to 0.12
nmols/200–250 g rat (figures 5 &6). The potency ranking
observed in the in vitro assay was matched in the rat in vivo
protection assay. Removing the carbohydrates associated
with the constant domains of the IgG did not reduce the
potency of the AVP-21D9 antibody. AVP-22G12 was also
potent at inhibiting the toxin in vivo at 1× , but not as
potent as AVP-21D9 at the 0.5× dose. Removal of the gly-
cosylation site in AVP-22G12 did impact on its potency
suggesting that although the effector functions are not
required, in the absence of the carbohydrates the overall
structure of the antibody is impacted to reduce its efficacy
to 80% survival at the designated 5 hour time point,
which dropped to 60% due to an additional death at 12
hours. At the lower dose of AVP-22G12 the time to death
was delayed significantly. AVP-1C6 at 1× was only 80%
protective and failed to protect or delay time to death at
the lower dose. The in vivo potency trend observed
AVP21D9 > AVP-22G12 > AVP-1C6, is the similar to the
potency in vitro and correlates well with affinity of anti-
body to PA. Moreover dosing rats with AVP-21D9 at 1× or
10× and challenging with lethal toxin the next day hours
or a week later with lethal toxin respectively were also pro-
tective as shown in figure 7.
High affinity human monoclonal PA neutralizing anti-
bodies may provide immediate neutralization of the
anthrax toxins. In this investigation we have accessed the
human IgG response to the PA83 component of AVA and
isolated a panel of high affinity potent PA neutralizing
monoclonal antibodies. These antibodies were selected
on the criteria of binding to PA83 (the form of the anthrax
toxin released by the bacteria prior to cell bound furin
processing) and inhibition of lethal toxin. This
technology will be particularly useful for the generation of
fully human monoclonal antibodies against various infec-
tious disease targets from vaccinated or naturally exposed
yet protected individuals. Moreover it may be possible to
access self-antibodies from autoimmune individuals.
Protection of rats from a lethal toxin challenge 17 hours and 1 week after administration of antibody Figure 7
Protection of rats from a lethal toxin challenge 17 hours and 1 week after administration of antibody Male 
Fisher 344 rats with jugular vein catheters weighing between 200–250 g were administered human anti-anthrax PA IgG mono-
clonal antibodies AVP-21D9 or the control human IgG in 0.2 ml PBS 0.1% BSA pH 7.4, 17 hours or 1 week later lethal toxin 
(PA 20 µg + LF 4 µg/200 g rat in 0.2 ml/ PBS 0.1% BSA pH 7.4) wasadministered. The dose of antibody was 0.25 and 2.5 nmols/
rat corresponding to 1× and 10× molar equivalent to the lethal toxin respectively. Five animals were used in each test group 
and four animals in each control. Test and control experiments were carried out at the same time using the same batch of 
reconstituted PA and LF toxins. Animals were monitored for discomfort and time of death, as assessed on the basis of cessa-
tion of breathing and heartbeat. Rats were maintained under anaesthesia for 5 hr post exposure to lethal toxin or until death 
to minimize discomfort.
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Conclusions
We have successfully engrafted human PBL's from
anthrax-vaccinated donors into SCID/bg mice and dem-
onstrated that a specific recall response can be selectively
enhanced by immunization with PA83. Moreover, we
have shown that the cells producing the antibodies can be
isolated, the transcript mRNA encoding the desired
antibodies can be readily recovered and stable recom-
binant cell lines producing human monoclonal antibod-
ies can be generated. The human monoclonal antibodies
generated are of very high affinity for PA83 and neutralize
lethal toxin in an in vitro cell based assay. Vaccination with
Anthrax Vaccine Adsorbed can induce the production of a
range of protective antibodies. Here we show that most of
the human anti-anthrax toxin antibodies selected by the
Xenerex technology™ are potent inhibitors of the lethal
toxin in vivo. The three parental antibodies and the two
aglycosylated forms described may be therapeutically use-
ful against anthrax infection and in the passive protection
of high risk individuals. In particular the two most potent
anthrax toxin-neutralizing antibody AVP-21D9 and AVP-
22G12 were completely effective at a dose corresponding
to 0.12 nmols/rat and 0.25 nmols/rat respectively.
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